H.C. Andersen Bio Pharma ApS: Financial statements 2019
CVR: 38683462
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
H.C. Andersen Bio Pharma ApS (CVR 38683462) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -11,237 and a net result of DKK -12,425 compared with DKK -191,065 the year before. Equity in the 2019 report amounted to DKK -169,145.
- Gross Profit
- DKK -11,237
- Profit/Loss
- DKK -12,425
- Equity
- DKK -169,145
- Total Assets
- DKK 23,428
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -11 t. | -12 t. | -169 t. | - |
| 2018 | 0 | -190 t. | -191 t. | -157 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
H.C. Andersen Bio Pharma ApS has published its annual report for 2018. Revenue came to DKK 0, and the net result was DKK -191,065.
About H.C. Andersen Bio Pharma ApS
H.C. Andersen Bio Pharma ApS was a Danish company of the type Anpartsselskab based in København S, founded in 2017. The company has been dissolved on 24 July 2026. The company was registered under the industry Detailhandel med andre nye varer. The company was previously named H. C. Andersen Emeren Group ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,673 compared with DKK -20,418 the year before. Equity in the 2025 report amounted to DKK -312,718.